瑞扎芬净早期使用:病例系列与文献综述
该病例系列报告了2024-25年某三级感染病中心门诊肠外抗菌治疗(OPAT)服务中6例成人患者使用新型棘白菌素瑞扎芬净的适应症、方案、结局与不良事件,并综述已发表病例、许可试验、抗菌谱及PK/PD与耐药倾向。瑞扎芬净中位疗程4剂(范围2-5),耐受良好,无实验室不良事件,所有患者均实现真菌学清除。
要点
- 6例患者适应症包括侵袭性和黏膜皮肤念珠菌病,以唑类耐药念珠菌为主。
- 首报瑞扎芬净联合伏立康唑治疗唑类难治性肺曲霉病一例。
核心结论
- 本中心早期使用及国际文献提示瑞扎芬净耐受良好、使用方便,是真菌治疗武器库的有用补充,尤其在门诊环境中。
研究设计与样本
- 纳入2024-25年通过OPAT服务接受瑞扎芬净治疗的全体成人患者,记录人口学、感染、治疗方案和结局,并综述已发表病例、许可试验、抗菌谱和PK/PD。
主要发现
- 6例患者(年龄范围30-84岁)于2024年7月至2025年2月接受瑞扎芬净治疗,适应症包括侵袭性和黏膜皮肤念珠菌病,以唑类耐药念珠菌为主。
- 瑞扎芬净中位疗程为4剂(范围2-5),总体耐受良好,无实验室不良事件。
- 所有患者均显示真菌学清除,结局积极。
关键数值与推荐
- 瑞扎芬净中位疗程4剂(范围2-5)。
- 选择瑞扎芬净而非每日棘白菌素的原因:患者偏好/便利(n=5)、担忧唑类耐药(n=4)、促进早期出院(n=2)。
临床怎么用
- 在OPAT服务中,瑞扎芬净每周一次静脉给药可用于成人侵袭性和黏膜皮肤念珠菌病,尤其唑类耐药者。
- 首例报告瑞扎芬净联合伏立康唑治疗唑类难治性肺曲霉病。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rezafungin is a novel echinocandin with a unique structural configuration enabling weekly IV dosing. We report on early use of rezafungin in our outpatient parenteral antibiotic therapy (OPAT) service, reviewing indications, treatment regimens, outcomes and adverse events in adult patients receiving rezafungin at a tertiary infectious disease centre. We also review published cases of rezafungin use, licensing trials, spectrum and pharmacokinetics/pharmacodynamics and how that might relate to its propensity to generate resistance (in comparison with daily echinocandins). METHODS: All adult patients who received rezafungin therapy via the OPAT service in 2024-25 were included. Patient demographics, infections, treatment regimens and outcomes were recorded. RESULTS: Six patients (age range 30-84 years) received rezafungin therapy between July 2024 and February 2025. Indications included invasive and mucocutaneous candidiasis, predominantly caused by azole-resistant Candida species. We also report the first case of using rezafungin in combination with voriconazole to treat azole-refractory pulmonary aspergillosis. Rezafungin courses were a median length of 4 doses (range: 2-5) and were generally well tolerated with no laboratory adverse events. Reasons for choosing rezafungin over daily echinocandins were patient preference/convenience (n = 5), concern regarding azole resistance (n = 4) and facilitation of earlier discharge (n = 2). One hundred and fifty-seven days with an IV catheter were saved through once-weekly dosing. Outcomes were positive, with all patients showing mycological clearance. CONCLUSIONS: Early use of rezafungin at our centre and in the international literature suggests it is a well-tolerated, convenient and useful addition to the antifungal armamentarium, particularly in the outpatient setting.
引用
- Davidson HC, Yau T, Dunstan I, et al. Early use of the novel antifungal rezafungin: a case series and literature review. J Antimicrob Chemother. 2025. PMID: 40366630. doi:10.1093/jac/dkaf143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。